pathogen. CD8
+ T-cells are a vital component of the acquired immune system. [2, 3] Effector-phenotype CD8 + memory T-cells (Tem) can trigger a rapid, potent, and effective immune response to specific antigens in the early stages of infection. Investigating the mechanism of differentiation of CD8 + T cells in the early stages of infection could provide new insights into effectively controlling infection in IPA patients with immune dysfunction. [4, 5] The mammalian target of rapamycin (mTOR) signaling pathway regulates cell metabolism, survival, growth, and proliferation. The mTOR downstream signaling pathway contains two key substrates, the ribosomal S6 kinase (S6K) and the eukaryotic translational initiation factor 4E binding protein 1 (4E-BP1). When activated, mTOR phosphorylates S6K and 4E-BP1 to promote protein translation and is sensitive to rapamycin inhibition. [6] Recent studies have shown that mTOR may regulate T-cell differentiation and adaptive immunity following the binding of the T-cell receptor to antigen. [7] In preliminary experiments, we found that mTOR modulates lymphocyte differentiation in immunosuppressed animals with fungal infections by regulating the transcription factors T-box expressed in T-cells (T-bet) and eomesodermin. [8] T-bet is a key transcription factor regulating T-cell differentiation and belongs to the T-box transcription factor family. [9] Eomesodermin plays a synergistic role in T-bet function and regulates the differentiation of CD8
+ T-cells into effector and memory T-cells. A recent study suggests that interleukin (IL)-12 can affect memory/effector CD8 + T-cell phenotype differentiation by regulating T-bet and eomesodermin.
[10] IL-12 can also enhance the activity of mTOR kinase in naïve CD8
+ T-cells. [11] In contrast, rapamycin inhibits the activity of mTOR kinase in CD8
+ T-cells, thereby blocking the expression of T-bet and promoting the expression of eomesodermin. Increased expression of eomesodermin in CD8 + T-cells may promote the generation of memory T-cells, while high expression of T-bet could promote effector CD8 + T-cell proliferation. [12] Triggering receptors expressed on myeloid cells (TREMs) were identified as a new family of receptors that regulate both innate and adaptive immune responses to infection. [13, 14] TREM-1 is mainly expressed on neutrophils, monocytes, and macrophages. High TREM-1 levels are indicative of acute or chronic conditions caused by fungi or bacteria. [14, 15] The TREM-1 extracellular domain can also be found as soluble TREM-1 (sTREM-1). It is proposed that sTREM-1 may arise directly from a splice variant or following the shedding of membrane-bound TREM-1 by metalloproteinase-mediated proteolytic cleavage. [16] sTREM-1 has proven to be a valuable diagnostic and prognostic marker since it is easily detected with immunochemical assays in biological fluid samples. Previous studies have found that sTREM-1 levels are elevated in plasma and bronchoalveolar lavage fluid from patients with bacterial or fungal pneumonia. [17, 18] In preliminary studies, we found that plasma sTREM-1 is closely correlated with T-bet and eomesodermin levels in immunocompromised Aspergillus-infected rats, suggesting that TREM-1 may be involved in lymphocyte regulation and differentiation during fungal infection. [19] Based on the theories and experimental results described above, we hypothesized that TREM-1 may play a vital role in mTOR modulation of CD8 + T-cell differentiation through the transcription factors T-bet and eomesodermin during the immune response to IPA.
Methods

Pathogen preparation
The strain of Aspergillus fumigatus, provided by the Department of Clinical Laboratory, Peking Union Medical College Hospital (PUMCH), was obtained from a case of pulmonary aspergillosis. Viable conidia (>95%) were obtained by growth on Sabouraud dextrose agar for 5 days at 35°C. Conidia were harvested in 10 ml 0.1% Tween-80/PBS and filtered through five layers of gauze. The concentration of conidia was adjusted to 1 × 10 8 CFU/ml by turbidity adjustment method. 
Animal model preparation
CD8
+ effector memory T-cells counts and interferon-γ, mammalian target of rapamycin, and S6 kinase expression 
Cytokine and soluble triggering receptors expressed on myeloid cell-1 quantification
Cytokines and sTREM-1 were quantified using the following ELISA kits as per the manufacturer's instructions; IL-6 (cat#: ab168538, Abcam), IL-10 (cat#: ab176665, Abcam), GM (cat#: 85-86051, Affymetrix Bioscience, San Diego, CA, USA), and sTREM-1 (cat#: SEA213Mu, USCN, Wuhan, China).
Statistical analysis
Data were analyzed using SPSS version 18.0 software (SPSS Inc., Armonk, NY, USA). All the data for the continuous variables in this study were proven to have normal distributions and are given as mean ± standard deviations (SD).
Results for continuous variables that were not normally distributed are given as medians (interquartile ranges) and were compared using nonparametric tests. Student's t-test or analysis of variance followed by Bonferroni's test were used to determine the statistical significance (P) of differences.
Pearson's correlation coefficient was used to analyze the correlation of two parameters. A value of P < 0.05 was considered statistically significant. 
Results
Tissue culture and histology
Regulation of the mammalian target of rapamycin pathway
As shown in Figure 2 , compared with the control group (0.25 ± 0.04, P = 0.004), IPA group (0.27 ± 0.04, P = 0.01), and CTX + IPA group (0.29 ± 0.04, P = 0.034), mTOR activity was significantly increased in the CTX + IPA + IL-12 group (0.39 ± 0.12). To verify that the induction of mTOR phosphorylation also led to its kinase activity, we monitored the kinetics of S6K, a direct target of mTOR kinase activity. As anticipated, IL-12 stimulation significantly enhanced the expression of S6K in CD8 + Tem (0.13 ± 0.03) compared with the control (0.06 ± 0.04, P < 0.001), IPA (0.07 ± 0.02, P = 0.001), and CTX + IPA (0.09 ± 0.01, P = 0.032) groups.
Similarly, when we blocked mTOR activity by adding rapamycin during IPA infection, we found that the expression of mTOR was significantly lower in the CTX + IPA + RAPA group (0.19 ± 0.05) compared with the CTX + IPA (0.29 ± 0.04, P = 0.034) and CTX + IPA + IL-12 (0.39 ± 0.12, P < 0.001) groups. The expression of S6K was also significantly lower in the CTX + IPA + RAPA (0.04 ± 0.04) group than in the CTX + IPA (0.09 ± 0.01, P = 0.01) and CTX + IPA + IL-12 (0.13 ± 0.03, P < 0.001) groups.
Mammalian target of rapamycin modulates CD8
+ T-cell differentiation and expression of triggering receptor expressed on myeloid cell-1
As shown in Figure 3 , the proportion of CD8 + Tem, IFN-γ production, and serum sTREM-1 expression were significantly increased in the CTX + IPA + IL-12 group (0.47 ± 0.06, 0.09 ± 0.03, and 1876.91 ± 247.80, respectively) compared with the CTX + IPA group (0.35 ± 0.10, P = 0.024; More importantly, we also found that adding rapamycin could significantly decrease the proportion of CD8 + Tem (0.22 ± 0.05), IFN-γ production (0.02 ± 0.01), and serum TREM-1 expression (1214.45 ± 293.24) compared with the CTX + IPA (0.35 ± 0.10, P = 0.017; 0.05 ± 0.04, P = 0.039; and 1537.64 ± 359.52, P = 0.022, respectively) and CTX + IPA + IL-12 (0.47 ± 0.06, P < 0.001; 0.09 ± 0.03, P < 0.001; and 1876.91 ± 247.80, P < 0.001, respectively) groups. These results indicate that sustained mTOR activity is essential for CD8 + Tem differentiation, Type I effector functions, and serum sTREM-1 expression.
Alteration of inflammatory responses and severity of fungal infection
IL-6 levels reflect the inflammatory response, and IL-10 levels reflect anti-inflammatory responses. Figure 4 shows that the IL-12-treated group had the highest IL-6 levels (2053.91 ± 402.37 pg/ml), followed by the CTX + IPA (1426.57 ± 488.03 pg/ml, P = 0.036), CTX + IPA + RAPA (822.74 ± 211.30 pg/ml, P < 0.001), IPA (811.58 ± 247.03 pg/ml, P < 0.001), and control (245.65 ± 85.78 pg/ml, P < 0.001) groups. In contrast, the concentration of IL-10 showed the reverse trend. The IL-10 level of the IL-12-treated group (314.94 ± 36.97 pg/ml), as well as the control (267.60 ± 46.10 pg/ml) and IPA (350.93 ± 43.11 pg/ml) groups, were significantly lower than the CTX + IPA group (437.95 ± 53.41 pg/ml, P < 0.001) and especially the CTX + IPA + RAPA group (542.44 ± 37.32 pg/ml, P < 0.001). Galactomannan (GM) is used to demonstrate the severity of fungal infection in clinical practice. In this study, we found that, after A. fumigates inoculation, the level of GM was significantly increased in the IPA (1985.98 ± 152.79 pg/ml, P < 0.001), CTX + IPA (2251.06 ± 230.50 pg/ml, P < 0.001), CTX + IPA + IL-12 (1920.15 ± 86.16 pg/ml, P < 0.001), and CTX + IPA + RAPA (2496.87 ± 278.05 pg/ml, P < 0.001) groups compared with the control group (126.82 ± 10.31 pg/ml). However, as shown in Figure 4 , treatment with IL-12 significantly decreased the level of GM compared with the CTX + IPA (P = 0.002) and CTX + IPA + RAPA (P < 0.001) groups.
discussion
In the current study, we demonstrated that IL-12 increased the number and effector response (IFN-γ release) of CD8 + Tem and the level of sTREM-1 during IPA infection in CTX-induced immunocompromised animals, through increased expression and activity of the mTOR signal transduction pathway. Furthermore, inflammatory cytokines (IL-6) were increased and anti-inflammatory cytokines (IL-10) were decreased significantly, which markedly affect the fungal burden of the host. These effects could be blocked by the mTOR inhibitor rapamycin.
CD8
+ T-cells play a vital role in the adaptive immune system. After infection, some of the CD8 + T-cells will display a memory phenotype and can survive long term. CD8
+ effector memory T-cells (CD8 + Tem), memory T-cells with effector cell phenotype, will establish a rapid immune response when the host comes into contact with the same pathogen, which is crucial for patients who are at a high risk of repeated infections such as immunosuppressed patients. [5, 20] The mTOR signaling pathway has the ability to sense cellular metabolic state, extracellular nutrient availability, presence of growth factors/cytokines, and control key cellular processes, including apoptosis/autophagy, proliferation, and cell growth that govern cell fate. Studies indicate that mTOR contributes to the proliferation and differentiation of T-cells in response to antigen stimulation. [7, 21] mTOR inhibition by rapamycin induces CD4
+ T-cell anergy and/or differentiation into FoxP3
+ regulatory T-cells and attenuates mTOR kinase signaling in regulating CD8
+ T-cell trafficking. [22, 23] Consistent with these results, the current study demonstrated that the presence of IL-12 augments mTOR activity and influences CD8 + Tem proliferation and Type I effector maturation following immunosuppression by CTX and A. fumigatus infection. Effector functions induced by IL-12 treatment were significantly attenuated by adding the mTOR inhibitor rapamycin, confirming that sustained mTOR kinase activity is required for IL-12-programed proliferation and Type I effector function in CD8 + Tem in response to a fungal infection.
TREM-1 is largely known as an activating receptor on neutrophils and monocytes, playing an important role in amplification of the inflammatory response. Studies demonstrated that activation of TREM-1 on monocytes drove robust production of pro-inflammatory chemokines such as monocyte chemoattractant protein 1 and IL-8. Engagement of TREM-1 in combination with microbial ligands that activate toll-like receptors also synergistically increased the production of the pro-inflammatory cytokines, TNF-α and IL-1β. [24, 25] Moreover, in primary human monocytes, TREM-1 activation was found to be upregulated in the context of host defense directed against bacterial and fungal infections. These cells had an improved ability to elicit T-cell proliferation and production of IFN-γ. The balance between the transcription factors T-bet and eomesodermin has been shown to determine effector and memory cell differentiation in CD8 + T-cells. Although in our previous studies, we found that both sTREM-1 and mTOR activity was significantly correlated with T-bet and eomesodermin levels in immunocompromised animals with IPA, little is known regarding its specific involvement in mTOR modulation of CD8 + T-cell differentiation and Type I effector function. [8, 19] Consistent with previous studies, the findings of the current study demonstrated that, similar to the number and effector cell response of CD8 + Tem, the level of serum sTREM-1 expression was also significantly increased after IL-12 treatment and significantly decreased after adding rapamycin. These findings suggest that the mTOR signaling pathway is the central regulator of transcriptional programs which determine effector and/or memory cell differentiation in CD8
+ T-cells through the transcription factors, T-bet and eomesodermin. Thus, sTREM-1 might be the molecular link between mTOR modulation and immune cell differentiation in the immunocompromised mice with a fungal infection. However, elucidation of a clear mechanism requires further study.
The current study also elucidated the final immune effects of the mTOR signal pathway. We found that IL-12 could increase plasma pro-inflammatory cytokine (IL-6) level, decrease the anti-inflammatory cytokine (IL-10), and reduce the fungal load (GM) significantly. The mTOR inhibitor rapamycin completely caused the opposite effects. These results indicated that the mTOR signaling pathway plays a vital role in CD8 + T-cell differentiation and function, resulting in changes of the immune response and fungal load in infected hosts with immunosuppression.
To summarize, mTOR could modulate CD8 + T-cell differentiation during immune responses to IPA. sTREM-1 may play a vital role in signal transduction between mTOR and the immune response. Whether this mechanism could be used as a target of antifungal immunotherapy in the future requires further study.
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